Advertisement

Topics

Ovid begins randomisation in Phase Ib/IIa trial of epilepsy drug

19:00 EDT 22 Aug 2017 | Net Resources International

Ovid Therapeutics has begun patient randomisation in a Phase Ib/IIa clinical trial of TAK-935 (OV935) to treat adults with rare epilepsies.

Original Article: Ovid begins randomisation in Phase Ib/IIa trial of epilepsy drug

NEXT ARTICLE

More From BioPortfolio on "Ovid begins randomisation in Phase Ib/IIa trial of epilepsy drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...